Literature DB >> 22595795

Interferon-β lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids.

M S Villaverde1, M L Gil-Cardeza, G C Glikin, L M E Finocchiaro.   

Abstract

We evaluated the effect of hIFNβ gene transfer alone or in combination with different antineoplastic drugs commonly used in cancer treatment. Five human tumor-derived cell lines were cultured as monolayers and spheroids. Four cell lines (Ewing sarcomas EW7 and COH, melanoma M8 and mammary carcinoma MCF-7) were sensitive to hIFNβ gene lipofection. Although this effect appeared in both culture configurations, spheroids showed a relative multicellular resistance (insensitive colon carcinoma HT-29 excluded). EW7 and M8 hIFNβ-expressing cells were exposed to different concentrations of bleomycin, bortezomib, carboplatin, doxorubicin, etoposide, methotrexate, paclitaxel and vincristine in both configuration models. In chemotherapy-sensitive EW7 monolayers, the combination of hIFNβ gene and antineoplastic drugs displayed only additive or counteractive (methotrexate) effects, suggesting that cytotoxic mechanisms triggered by hIFNβ gene lipofection could be saturating the signaling pathways. Conversely, in chemotherapy-resistant EW7 spheroids or M8 cells, the combination of hIFNβ with drugs that mainly operate at the genotoxic level (doxorubicin, methotrexate and paclitaxel) presented only additive effects. However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNβ gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine). The great bystander effect induced by hIFNβ gene lipofection could be among the main causes of its effectiveness, because only 1 or 2% of EW7 or M8 hIFNβ-expressing cells killed more than 60 or 80% of cell population, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595795     DOI: 10.1038/cgt.2012.27

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.

Authors:  Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2020-02-14       Impact factor: 6.389

Review 2.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

3.  Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Authors:  Liliana M E Finocchiaro; Chiara Fondello; María L Gil-Cardeza; Úrsula A Rossi; Marcela S Villaverde; María D Riveros; Gerardo C Glikin
Journal:  Hum Gene Ther       Date:  2015-05-26       Impact factor: 5.695

Review 4.  3D tissue-engineered model of Ewing's sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Marco Santoro; Vandhana Ramammoorthy; Brian A Menegaz; Geoffrey Bartholomeusz; Lakesla R Iles; Hesham M Amin; J Andrew Livingston; Antonios G Mikos; Joseph A Ludwig
Journal:  Adv Drug Deliv Rev       Date:  2014-08-07       Impact factor: 15.470

Review 5.  Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine.

Authors:  Gianluca Colella; Flavio Fazioli; Michele Gallo; Annarosaria De Chiara; Gaetano Apice; Carlo Ruosi; Amelia Cimmino; Filomena de Nigris
Journal:  Int J Mol Sci       Date:  2018-02-21       Impact factor: 5.923

6.  Therapeutic potential of bleomycin plus suicide or interferon-β gene transfer combination for spontaneous feline and canine melanoma.

Authors:  Lucrecia Agnetti; Chiara Fondello; Marcela S Villaverde; Gerardo C Glikin; Liliana M E Finocchiaro
Journal:  Oncoscience       Date:  2017-12-28

Review 7.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.